Poyrazoglu Orhan Kursat, Dogukan Ayhan, Yalniz Mehmet, Seckin Dilara, Gunal Ali Lhsan
Departments of Internal Medicine, Nephrology, and Biochemistry, Medical Faculty, Firat Medical Center of Firat University, 23200 Elazig, Turkey.
Ren Fail. 2006;28(8):723-7. doi: 10.1080/08860220600925594.
Atherosclerotic cardiovascular diseases caused by traditional and non-traditional risk factors are the most common cause of morbidity and mortality in hemodialysis patients. Recently, much interest has been focused on non-traditional factors, such as oxidative stress, inflammation, and endothelial dysfunction. Hemodialysis patients are not only exposed to oxidative stress but also to inflammation. Although anticoagulants are the most frequently used drugs in hemodialysis patients, their effect upon oxidative stress and inflammation in dialysis patients are still unknown.
Thirty-three hemodialysis patients were randomized into three groups. Group 1 received standard heparin while group 2 received low molecular weight heparin during the dialysis therapy. Group 3 (control group) did not receive any anticoagulant agent. Investigators were blinded to the therapy. Serum concentrations of oxidative stress and inflammation markers, including C-reactive protein, tumor necrosis factor alpha, superoxide dismutase, and malondialdehyde, were measured before and after dialysis session.
The oxidative stress and inflammation markers were significantly increased in groups 1 and 3 (p < 0.05 for each) compared to their baseline values. In contrast, baseline and end-treatment values of the oxidative stress and inflammation markers were comparable in the group 2 (p > 0.05).
These findings indicate that the type of anticoagulants may take a role in the acute effect of hemodialysis upon oxidative stress and inflammation markers. A comparison of the groups revealed that low molecular weight heparin decreased the oxidative stress and inflammation, whereas standard heparin increased the oxidative stress and inflammation. Low molecular weight heparin appears to have an additive benefit for hemodialysis patients.
由传统和非传统危险因素引起的动脉粥样硬化性心血管疾病是血液透析患者发病和死亡的最常见原因。最近,人们的兴趣多集中在非传统因素上,如氧化应激、炎症和内皮功能障碍。血液透析患者不仅暴露于氧化应激,还暴露于炎症。尽管抗凝剂是血液透析患者最常用的药物,但其对透析患者氧化应激和炎症的影响仍不清楚。
33例血液透析患者被随机分为三组。第1组在透析治疗期间接受标准肝素,第2组接受低分子量肝素。第3组(对照组)不接受任何抗凝剂。研究人员对治疗情况不知情。在透析前后测量血清氧化应激和炎症标志物的浓度,包括C反应蛋白、肿瘤坏死因子α、超氧化物歧化酶和丙二醛。
与基线值相比,第1组和第3组的氧化应激和炎症标志物显著增加(每组p < 0.05)。相比之下,第2组氧化应激和炎症标志物的基线值和治疗结束时的值具有可比性(p > 0.05)。
这些发现表明,抗凝剂的类型可能在血液透析对氧化应激和炎症标志物的急性影响中起作用。组间比较显示,低分子量肝素可降低氧化应激和炎症,而标准肝素则增加氧化应激和炎症。低分子量肝素似乎对血液透析患者有额外的益处。